Skip to main content
Selim Arcasoy, MD, Pulmonology, New York, NY, New York-Presbyterian Hospital


Pulmonology New York, NY

Critical Care Medicine, Cystic Fibrosis, Interstitial Lung Diseases, Lung Transplantation Medicine

Professor of Medicine, Columbia P&S

Overview of Dr. Arcasoy

Dr. Arcasoy was recruited to Columbia University/NewYork-Presbyterian Hospital as the Medical Director of Lung Transplant Program in 2001 from the University of Pennsylvania, where he was a key member of the Advanced Lung Disease and Lung Transplantation Program. After his recruitment, he completely turned around the Lung Transplant Program to rank amongst the top 5 to 10 programs in the country with regards to volume and top 1 to 5 programs in terms of patient survival. Under his leadership, the Lung Transplant Program has performed 60-70 transplants annually in the past 7 years with a record number of 84 transplants in 2019. Despite high transplant volumes and very sick pretransplant candidates, the survival of lung transplant recipients has remained significantly above the national average. Currently, 1-year survival of lung transplant recipients at Columbia University is 90%, 5-year survival 68%, and 10-year survival 45%.
Dr. Arcasoy has gained national and international reputation with various leadership roles in many professional organizations and scientific societies. He previously chaired the Thoracic Organ Transplant Committee of the American Society of Transplantation and the Transplant Network Steering Committee of the American College of Chest Physicians. Dr. Arcasoy is a Fellow of the American College of Physicians (FACP), American College of Chest Physicians (FCCP), and American Society of Transplantation (FAST). He serves as a reviewer for many scientific journals. Dr. Arcasoy has been named in America's Top Doctors and Top Doctors: New York Metro area in the past 17 consecutive years. He has also been selected in the New York Times Super Doctors list in the past 10 years.
Dr. Arcasoy's main research interests include outcomes of patients with advanced lung disease before and after lung transplantation and clinical trials in new immunosuppressive therapies.

Education & Training

  • Columbia University
    Columbia UniversityM.P.H., Public Health in Healthcare Management, 2011 - 2013
  • UPMC Medical Education
    UPMC Medical EducationFellowship, Pulmonary Disease and Critical Care Medicine, 1994 - 1998
  • SUNY Health Science Center at Brooklyn
    SUNY Health Science Center at BrooklynResidency, Internal Medicine, 1990 - 1994
  • Ege Univ- Fac Med
    Ege Univ- Fac MedClass of 1990
  • Tarsus American College
    Tarsus American CollegeBachelors, 1977 - 1984

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2004 - 2023
  • PA State Medical License
    PA State Medical License 1994 - 2002
  • NY State Medical License
    NY State Medical License 1993 - 2023
  • CT State Medical License
    CT State Medical License 1992 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Critical Care Medicine
  • American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2003-2014, 2016-2020
  • New York Magazine: Top Doctors Castle Connolly, 2002-2007, 2010, 2019-2020
  • New York City Super Doctors New York Times Magazine, 2009-2020
  • Join now to see all

Clinical Trials

Publications & Presentations


Journal Articles

  • Interobserver variability in grading transbronchial lung biopsies after lung transplantation  
    Chest, 1/1/2013
  • Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis  
    Eur Resp J, 1/1/2013
  • Variation in PTX3 is Associated With Primary Graft Dysfunction After Lung Transplantation  
    Am J Respir Crit Care Med, 1/1/2012
  • Join now to see all

Books/Book Chapters

  • Join now to see all


  • PTX3 Polymorphisms Are Associated with Primary Graft Dysfunction after Lung Transplantation
    J Heart Lung Transplant, 1/1/2011
  • Elevated PTX3 Concentration Is Associated with Primary Graft Dysfunction after Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis
    J Heart Lung Transplant, 1/1/2011
  • Donor Lung Surfactant Protein D Gene Polymorphisms are Associated with Bronchiolitis Oblietrans Syndrome and Mortality after Lung Transplantation
    J Heart Lung Transplant, 1/1/2011
  • Join now to see all


  • International Collaboration in Lung Transplantation 
    Istanbul, Turkey - 1/1/2013
  • Lung Transplantation. 2013 Update 
    Medica Health Clinic, Istanbul, Turkey - 1/1/2013
  • Lung Transplantation in Interstitial Lung Disease and Pulmonary Fibrosis 
    Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, White Plai - 1/1/2012
  • Join now to see all


Press Mentions

  • Lung Patients See a New Era of Transplants
    Lung Patients See a New Era of TransplantsSeptember 24th, 2006

Grant Support

  • Pathogenesis Of Airway Disease In Cystic FibrosisNational Heart, Lung, And Blood Institute1996–1997

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS North Carolina BlueOptions PPO
    CIGNA Open Access
    Great West PPO
    Healthfirst New York
    HIP of New York - Select PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment